OPTN OptiNose

Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference

YARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 at 10:00 a.m. ET.

To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.

A replay of the webcast will be available for 30 days following the conclusion of the event.

About Optinose

Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit  or follow us on and .

Optinose Investor Contact

Jonathan Neely

267.521.0531



EN
26/08/2024

Underlying

OPTNOptiNose

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptiNose

 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Announces Reporting Date for Third Quarter 2024 Financial Res...

Optinose Announces Reporting Date for Third Quarter 2024 Financial Results Conference Call and Webcast to be held November 12, 2024, at 8:00 a.m. Eastern Time YARDLEY, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2024 and corporate updates, before market open, on Tuesday, November 12, 2024. Company to Host Conference CallMembers of the Company’s leadership team will host a conference call to...

11h / 18m 1 EN
 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) YARDLEY, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option awards to purchase an aggregate of 185,000 shares of its common stock to eight new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in accordance with Nasd...

October 16, 2024 1 EN
 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose Appoints Terry Kohler as Chief Financial Officer

Optinose Appoints Terry Kohler as Chief Financial Officer YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler was most recently the Chief Financial Officer for Verrica Pharmaceuticals, a dermatology therapeutics company, where he supported commercial preparations for the launch of a topical treatment for molluscum contagiosum and research and development pipeline investments. Mr. Kohl...

October 7, 2024 1 EN
 PRESS RELEASE
Free
OPTN OPTINOSE

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhi...

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review publication of a paper titled, “EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials”1 in the , the journal of the American Rhinologic Society. As discussed in the public...

September 5, 2024 1 EN
 PRESS RELEASE
Free
OPTN OPTINOSE

Optinose to Present at the H.C. Wainwright 26th Annual Global Investme...

Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference YARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 at 10:00 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast ...

August 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch